Navigation Links
Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
Date:3/3/2008

nce to the cash flow statement, represents the net cash the Company spent in conducting its operational activities, excluding net proceeds resulting from its investment and financing activities. The Company's net burn rate in 2007 amounted to euro 29.5 million, compared to euro 17.8 million in 2006. This significant increase in the net burn rate, notwithstanding the increase in payments relating to collaboration and development agreements received by the Company, for an aggregate amount of euro 14.0 million in 2007, is explained by the significant increase in the operational expenses incurred by the Company in 2007. NicOx expects its burn rate to continue to further increase very strongly over the coming financial years, as a result of the anticipated expenses related to the clinical development and the launch preparation activities for its drug candidate naproxcinod, currently in phase 3 clinical development.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, glaucoma and Chronic Obstructive Pulm
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
3. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
4. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Biopure Announces 2007 Third Quarter Financial Results
8. Xytis Names Gordon H. Busenbark as Chief Financial Officer
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Pharmacopeia Announces Third Quarter 2007 Financial Results
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015  Hill-Rom Holdings, Inc. (NYSE: ... Seng has been elected to its Board of ... Residence for Covidien, as well as President of Covidien,s ... Peripheral Vascular from 2010 to 2012. Ms. ... acquisition of ev3 Incorporated, where she was a founding ...
(Date:3/4/2015)... March 4, 2015 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China, today announced ... year 2014. Fourth Quarter 2014 Financial ... quarter of 2014 increased by 36.2%, or 36.8% excluding ... $58.0 million from $42.6 million in the same quarter ...
(Date:3/4/2015)... , March 4, 2015 Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... will ring The Opening Bell ® of the ... 2015. Asterias began trading as an NYSE MKT listed ... York Stock Exchange is a trusted partner to Asterias ...
Breaking Medicine Technology:Hill-Rom Elects Stacy Enxing Seng to its Board of Directors 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
... , LACHEN, Switzerland , Jan. ... of plasma products in the world, today announced that it has received ... Food and Drug Administration (FDA). The approval was granted for the ... bleeding episodes in patients with severe von Willebrand disease (VWD) as well ...
... , SUNNYVALE, Calif. , Jan. 13 ... of radiosurgery, today announced that it will report results for its fiscal second ... 4, 2010 after the market closes. , A conference call to review ... EST and will be hosted by Euan S. Thomson , Ph.D., ...
Cached Medicine Technology:Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 5Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 6Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010 2Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010 3
(Date:3/4/2015)... (PRWEB) March 04, 2015 The ... subjectivity in density assessment and help improve breast ... numerous abstracts accepted for presentation at the European ... Ten abstracts - eight posters and 2 ... Solutions’ automated breast density and quantitative breast imaging ...
(Date:3/4/2015)... Starting February 2015, Dr. Joseph King ... at their new location in Surrey. , In addition ... Dr. Gabriel Chu also provide comprehensive ophthalmology services, including ... Fraser Valley Cataract and Laser (FVCL). This state of ... of Physicians and Surgeons of British Columbia. Fraser Valley ...
(Date:3/4/2015)... State officials have awarded $82,500 to ... Public Health at Georgia State University, to support the ... Georgia’s Division of Family and Children Services (DFCS) as ... Center. , The 1-800-CHILDREN Helpline is a top ... referral services that promote the wellbeing of children while ...
(Date:3/4/2015)... 04, 2015 Organic Valley, the nation’s largest ... announced its cause campaign to Save the Bros, http://savethebros.com/ ... making a difference to Bros everywhere. To date, the ... Facebook. The video was named Adweek’s best commercial of ... Mashable and Digiday, among other media outlets. , “We ...
(Date:3/4/2015)... March 04, 2015 SIGVARIS ... technology and their first compression therapy collection designed exclusively ... this collection, SIGVARIS USA is proud to announce the ... product line. , Constructed from a unique, extremely fine ... in mind. These socks and thigh-highs offer a tailored ...
Breaking Medicine News(10 mins):Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:King LASIK relocates to Surrey, British Columbia 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2
... The holiday season is here,which for most Americans ... homes bustling with family and friends. All of this ... risk for contracting,viruses, particularly influenza. Maxim Health Systems is ... have not already done so, not only,to protect themselves ...
... FRANCISCO, Calif., Oct. 29 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... president and chief operating officer, will present,a company overview ... 3 at 3:20 p.m. EST at The Waldorf Astoria ... audio webcast or the subsequent archived recording,log on to ...
... Oct. 29 SkinMedica, Inc.,s 45 sales,consultants from ... to,take part in a spectacular sales meeting at ... joined by an additional 40 employees,from sales, marketing, ... operations. CEO Mary Fisher kicked off the meeting,with ...
... tesamorelin, a Phase III compound being investigated ... patients with lipodystrophy -- Theratechnologies to receive up ... in the US -- Merck KGaA, Darmstadt, Germany, of which ... equity investment in Theratechnologies -- EMD Serono acquires option to ...
... -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: ... company that develops, manufactures and markets advanced ... will be attending the,Credit Suisse Asian Healthcare ... Location: Beijing, China, China Medical Technologies, ...
... makes a Sustainable Transition with SafePath,s ADA Approved, ... CHICO, Calif., Oct. 29 For nearly 40 ... is not just,a decision of who to vote ... at all.,Despite federal and state regulations mandating compliance ...
Cached Medicine News:Health News:Give the Gift of Good Health This Holiday Season - Remind Friends and Family to Get a Flu Shot 2Health News:Give the Gift of Good Health This Holiday Season - Remind Friends and Family to Get a Flu Shot 3Health News:SkinMedica Hosts Aesthetics Division National Sales Meeting 2Health News:SkinMedica Hosts Aesthetics Division National Sales Meeting 3Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 2Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 3Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 4Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 5Health News:SafePath(TM) Products Provides Universal Access for Ohio Voters 2
... is a 2-megapixel, 12-bit FireWire digital camera. Comes complete ... effortlessly. Imaging has never been this easy! Choose from ... CCD - 2/3" Color Bit Depth ... - 500 microseconds - 60 seconds Hardware ...
... camera incorporates a Progressive Scan 1/2" CCD with ... x 960 (V) SXGA. Whats more the XCD-SX910CR ... called a "Bayer filter") and outputs the "raw ... to be converted to a color image on ...
... monochrome " 1.3 Megapixel FireWire camera suitable ... to simplify real-time uncompressed video display and ... video and digital still-image quality in an ... ideal for industrial inspection tasks involving brightfield ...
... GT-CAPTURE digital camera photomicrographic system can be ... as Olympus, Leica, Nikon, and Zeiss, making ... images over the Internet easy and fast. ... performance-proven Nikkor lens. The system records photomicrographic ...
Medicine Products: